Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-4914

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4914). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904914)

Losartan Potassium 100 mg film-coated tablets by A-S Medication Solutions. The white rectangular product label shows the NDC 50090-4914-0 and states that each film-coated tablet contains 100 mg of losartan potassium USP. It instructs to store at 68 to 77 degrees Fahrenheit and protect from light. The package contains 90 tablets.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Atenolol (dotted line) and Losartan Potassium (solid line). The graph indicates an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Atenolol and Losartan Potassium. The x-axis represents study months, and the y-axis shows the percentage of affected patients. The graph indicates an adjusted risk reduction of 25% with Losartan Potassium (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups,' showing comparative hazard ratios between Losartan Potassium and Atenolol for primary composite events and stroke (fatal/non-fatal). The chart includes multiple subgroups such as age, gender, race, ISH, diabetes, and history of cardiovascular disease, with event rates and hazard ratios presented visually along a central reference line favoring each treatment group.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan potassium versus placebo. The vertical axis shows percentage of patients, and the horizontal axis shows time in months. The graph includes statistical data indicating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.